Announcements Trials
Browse Landscape

Phase

Phase 2 1

Status

Completed 19Terminated 2Recruiting 2Unknown 1Active not recruiting 1

Sponsor Class

OTHER 1

Study Type

Interventional 1

Sponsor

Cancer Type

Tumor-Agnostic 1

Conditions

Carcinoma, Non-Small-Cell Lung 8Esophageal Squamous Cell Carcinoma 4Pancreatic Neoplasms 2NSCLC 2Carcinoma, Squamous Cell 2Triple Negative Breast Neoplasms 1Squamous Cell Carcinoma of Head and Neck 1Pathologic Complete Response 1PFS 1Neoplasms 1NRG1-fused Non-small Cell Lung Cancer 1Gastrointestinal Neoplasms 1Focus of Study Instead 1EGFR Mutation Positive Non-small Cell Lung Cancer 1Colorectal Neoplasms 1Cancers Harbouring an EGFR Mutation, (Excluding Non-squamous Non- Small Cell Lung Cancer, a Registered Indication), a HER2 Mutation or a HER3 Mutation 1Breast Neoplasms 1Brain Neoplasms 1

Interventions

Exercise 19Drug Therapy 18pembrolizumab 13Capecitabine 11Blood Specimen Collection 11Surveys and Questionnaires 10Radiotherapy 10Paclitaxel 9Dexamethasone 9Nivolumab 8Standard of Care 7Oxaliplatin 7Fluorouracil 7Erlotinib Hydrochloride 7apatinib 6Interviews as Topic 6Gemcitabine 6Control Groups 6Cisplatin 6Therapeutics 5Neoadjuvant Therapy 5Mindfulness-Based Cognitive Therapy 5Metformin 5Injections 5Everolimus 5Docetaxel 5Cyclophosphamide 5Bevacizumab 5sintilimab 4atezolizumab 4

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Unknown × Neoplasms × Afatinib × Clear all
NCT03239015 2022-03-04

Efficacy and Safety of Precision Therapy in Refractory Tumor

Shanghai Changzheng Hospital

Phase 2 Unknown
300 enrolled
Tumor-Agnostic

Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon âš¡